Cross-sectional Surveys: Impact of Kidney-CAP availability on health provider and patient decisions related to vascular access, dialysis modality and kidney transplantation

This cross-sectional survey study demonstrates that the availability of the Kidney-CAP bleeding cessation device positively influences clinical decision-making by increasing patients' desire for arteriovenous fistula creation and kidney transplantation, while prompting healthcare providers to recommend home hemodialysis more frequently.

The Gist

Imagine you are a gardener who has just planted a very special, high-pressure water hose in your garden. This hose (which, in the medical world, is an arteriovenous fistula or AVF) is essential for watering your plants (keeping a patient alive on dialysis). However, there's a scary risk: if the hose gets a leak or a hole, water can spray out with such force that it could flood the whole yard and cause a disaster.

For years, doctors and patients have been terrified of this "flood." This fear has stopped many people from planting the hose in the first place, or has made them want to move to a different, less efficient watering system entirely.

This research paper is about a new invention called the Kidney-CAP. Think of it as a super-strong, custom-made emergency shut-off valve or a "magic lid" that you can snap onto the hose instantly if it starts spraying. It's designed to stop the bleeding immediately, even if you are at home, far away from the hospital.

The researchers wanted to know: "If we tell patients and doctors that this 'magic lid' exists, will it change their minds about how they manage their kidney disease?"

Here is what they found, broken down simply:

1. The "Magic Lid" Changes the Patient's Mind

Before this study, many patients were so scared of the hose leaking that they refused to get the fistula (the best type of access) or were desperate to get a kidney transplant just to get off dialysis entirely.

• The Result: When patients learned about the Kidney-CAP, they felt much safer.
  • More patients said "Yes" to the fistula: Patients who were on the fence about getting the "hose" installed felt more confident doing it because they knew they had a safety net.
  • More patients wanted a transplant: Interestingly, knowing they had a safety device made current dialysis patients more eager to get a kidney transplant. It's like realizing, "I have a life jacket, so I'm not afraid to jump into the deep end to find a better way to swim." The safety device reminded them of the risks of staying on dialysis, motivating them to seek a permanent cure.

2. The Doctors' Perspective: A Shift in Strategy

The doctors (nephrologists) were asked the same question: "If your patient has this safety lid, would you recommend different treatments?"

• The Result: The doctors didn't change their minds about the fistula or the transplant. They still thought those were the right choices regardless of the lid.
• However, they did become more open to suggesting Home Hemodialysis.
  • The Analogy: Imagine a parent letting their teenager drive a car. If the car has a brand-new, high-tech emergency brake that the teen can use instantly, the parent might feel more comfortable saying, "Okay, you can drive to the grocery store on your own." Similarly, knowing the patient has a Kidney-CAP made doctors feel safer recommending that patients do their dialysis at home rather than in a clinic.

3. When to Introduce the "Lid"

The study also asked: When is the right time to show this device to a patient?

• Too Early: Showing it to someone who hasn't even decided to start dialysis yet is like giving a parachute to someone who hasn't decided to jump out of a plane yet. It's too soon.
• Too Late: Showing it to someone who is already bleeding heavily is like handing them a parachute after they've already hit the ground.
• Just Right: The best time is when a patient has decided, "I'm going to do dialysis," and is now looking at their options for the "hose." That is the moment the Kidney-CAP gives them the confidence to move forward.

The Bottom Line

This study is the first to look at how a simple safety tool can change the entire conversation about kidney disease.

Think of the Kidney-CAP not just as a piece of plastic, but as a fear-buster. By removing the terrifying possibility of a catastrophic leak, it empowers patients to make bolder, better health choices—like getting the best vascular access or pursuing a transplant—and gives doctors the confidence to let patients take more control of their treatment at home.

In short: A little safety device gave big confidence to everyone involved, leading to better decisions for kidney health.

Technical Summary

1. Problem Statement

Patients undergoing hemodialysis (HD) with arteriovenous fistulas (AVF) or arteriovenous grafts (AVG) face a significant risk of catastrophic, potentially fatal hemorrhage, particularly outside the controlled environment of a dialysis facility. While guidelines exist for managing bleeding within the facility, strategies for out-of-hospital bleeding are limited.

• The Gap: Previous campaigns (e.g., UK's "Put a Lid On It," Australia's "Stop the Bleed") introduced bleeding cessation devices, but evidence regarding their impact on clinical decision-making is lacking.
• The Question: Does the availability of a specific bleeding cessation device, the Kidney-CAP (a 3D-printed device approved by Health Canada and the FDA), influence the decisions of patients and healthcare providers (HCPs) regarding:
  1. Vascular access creation (AVF/AVG).
  2. Dialysis modality (specifically home hemodialysis).
  3. Pursuit of kidney transplantation.

2. Methodology

The study employed a cross-sectional survey design conducted at a Canadian academic nephrology program (Western University/London Health Sciences Centre) between January 2024 and October 2025.

• Participants: Three distinct groups were surveyed:
  1. Health Care Providers (HCP): 18 respondents (nephrologists, nurses, vascular access coordinators).
  2. CKD-HD Patients: 23 patients currently on in-center hemodialysis.
  3. CKD-Clinic Patients: 30 patients with advanced chronic kidney disease (CKD) not yet on dialysis but at high risk of renal failure.
• Intervention: All participants were presented with an information page containing a photograph and instructions on the Kidney-CAP (Appendix 1).
• Survey Instrument:
  • Likert scale questions (ranging from "significantly decrease" to "significantly increase") were used to assess the impact of Kidney-CAP availability on specific clinical decisions.
  • HCPs were presented with four clinical scenarios (varying by CKD stage and access type) to gauge recommendations.
  • Patients were asked about their willingness to undergo AVF/AVG creation, switch to home HD, or pursue transplantation.
• Statistical Analysis:
  • Data was analyzed using StataMP 18.0.
  • A two-tailed, one-sample sign test was used to determine if the median response differed significantly from the neutral "no effect" response ($p < 0.05$).
  • Missing data was handled via listwise deletion.

3. Key Contributions

• First-of-its-kind Assessment: This is the first study to evaluate the perceived benefit of a bleeding cessation device specifically regarding its influence on the "decision-making journey" of CKD patients (access, modality, and transplant).
• Provider vs. Patient Alignment: It highlights the divergence between HCP recommendations and patient preferences when a safety device is introduced.
• Timing of Education: The study provides data-driven insights into the optimal timing for introducing bleeding cessation education within the CKD care pathway.

4. Key Results

A. Healthcare Provider (HCP) Decisions

• Vascular Access & Transplant: The availability of the Kidney-CAP had no significant impact on HCP recommendations for AVF/AVG creation or kidney transplantation across any clinical scenarios.
• Dialysis Modality: The availability of the Kidney-CAP significantly increased HCP recommendations for home hemodialysis in two specific scenarios:
  1. ESKD patients on HD for 1 month using a Central Venous Catheter (CVC) ($p=0.039$).
  2. ESKD patients on HD for 1 month with an AVF experiencing prolonged bleeding ($p=0.039$).
• Education Timing: HCPs felt introducing the device was "too early" for pre-dialysis CKD patients (Stage G5A2) and "too late" for patients already experiencing prolonged bleeding. The "right timing" was identified for patients who had chosen HD and were evaluating access options (e.g., those on CVC).

B. Patient Decisions (CKD-HD Group - On Dialysis)

• Vascular Access & Modality: No significant change in the desire to create a new AVF/AVG or switch to home HD.
• Transplantation: The availability of the Kidney-CAP significantly increased the desire to undergo kidney transplantation ($p=0.031$).
• Usability: Patients reported that using the device would be "very easy" or "easy" ($p=0.001$).

C. Patient Decisions (CKD-Clinic Group - Pre-Dialysis)

• Vascular Access: Awareness of the Kidney-CAP significantly increased the desire to undergo AVF/AVG creation ($p=0.020$).
• Transplantation & Modality: No significant impact on the desire for transplantation or switching to hemodialysis (for those considering peritoneal dialysis).

5. Significance and Discussion

• Mitigating Fear: The results suggest that the Kidney-CAP addresses the specific fear of catastrophic bleeding that often deters patients from choosing AVF/AVG (the gold standard for vascular access). By providing a safety net, patients in the pre-dialysis clinic were more willing to commit to AVF creation.
• Transplant Motivation: For patients already on dialysis, the device may serve as a tangible reminder of the risks associated with long-term dialysis, thereby incentivizing the pursuit of kidney transplantation as a safer long-term solution.
• Clinical Implementation: The study suggests that introducing the Kidney-CAP is most effective when a patient has decided on hemodialysis but is still evaluating vascular access options. Introducing it too early (pre-decision) or too late (after a bleeding event) is less effective.
• Limitations: The study relied on self-reported desires rather than actual clinical outcomes, had a low response rate (particularly among patients), and was conducted at a single center with a predominantly Caucasian demographic, limiting generalizability.

Conclusion

The Kidney-CAP is associated with increased patient willingness to undergo AVF/AVG creation and kidney transplantation. While it did not alter HCP recommendations for access or transplant, it did increase their recommendation of home hemodialysis in high-risk scenarios. The device appears to function as a psychological safety mechanism that reduces fear-based barriers to optimal vascular access and transplantation. Further research is needed to validate these findings in diverse populations and to track actual clinical decision outcomes.